Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2019-04-24 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于受让高林厚健（上海）创业投资合伙企业（有限合伙）财产份额暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a related-party transaction where Shenzhen BGI Genomics Co., Ltd. (华大基因) is acquiring a 7.5% property share in a limited partnership fund from a related party, Gao Lin (Shenzhen) Capital Management Co., Ltd. The document includes extensive information about the transaction, the parties involved, their financials, the agreements signed, and the regulatory compliance aspects. It is a formal disclosure of a capital investment transaction involving related parties, with detailed terms and conditions of the transfer and the impact on shareholding structure. There is no indication that this is a full annual or interim financial report, audit report, earnings release, or other financial statement. It is not a call transcript, nor a voting result announcement. The document is a regulatory announcement about a capital transaction and related party dealings. According to the filing definitions, this fits best under Capital/Financing Update (CAP) as it concerns updates on company fundraising, financing activities, or capital structure changes. The document length and detail confirm it is not a mere announcement of a report (RPA) or a regulatory filing (RNS) fallback. Therefore, the classification is CAP with high confidence.
2019-04-24 Chinese
关于使用暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen BGI Genomics Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It details the board meeting resolution, investment purpose, investment products, investment limits, risk analysis, and approvals by the board, independent directors, supervisory board, and sponsor institution. The document does not contain financial statements or detailed financial data but is a formal disclosure about the company's decision to use idle raised funds for low-risk bank wealth management products. It is a regulatory announcement about capital usage and management rather than a financial report or earnings release. The document length is 4367 characters, which is relatively short and consistent with an announcement. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on the company's use of raised capital funds for cash management purposes.
2019-04-24 Chinese
关于2019年度公司及下属子公司向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Shenzhen BGI Genomics Co., Ltd. regarding the company's and its subsidiaries' application for a comprehensive credit facility from banks for the year 2019. It details the proposed credit limits from various banks, the purpose of the credit, and the authorization for management to handle related legal documents. The document is short (1154 characters) and focuses on financing activities, specifically credit facilities and loans. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is clearly an update on the company's capital/financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-04-24 Chinese
2018年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year ended December 31, 2018, issued by Shenzhen BGI Genomics Co., Ltd. It discusses the company's internal control systems, evaluation scope, control activities, risk assessments, and conclusions about the effectiveness of internal controls, including financial reporting controls. The document references regulatory frameworks and standards related to internal control and compliance, and it includes detailed descriptions of control procedures and defect classifications. It is a comprehensive report on internal control evaluation rather than a general annual report or audit report. The content aligns with an Audit Report / Information (AR) filing, which covers audit-related findings, applied accounting principles, and internal control evaluations, but is distinct from a full Annual Report (10-K) or Management Discussion & Analysis (MDA). The document length (9,349 characters) and detailed substantive content support classification as AR rather than a brief announcement or certification. Therefore, the filing type is AR with high confidence. FY 2018
2019-04-24 Chinese
2018年年度审计报告
Annual Report Classification · 100% confidence The document is titled as "已审财务报表 2018 年度" which translates to "Audited Financial Statements for the year 2018". It contains detailed financial statements including consolidated balance sheets, profit and loss statements, cash flow statements, and notes to the financial statements. There is a comprehensive audit report from Ernst & Young (安永华明) with audit opinions, basis for opinions, key audit matters, and responsibilities of management and auditors. The document includes extensive financial data and disclosures for the fiscal year ending December 31, 2018. The length is about 15,000 characters, indicating a full report rather than a brief announcement or certification. This matches the definition of an Annual Report (10-K) which covers the full financial performance and company activity for the year. Although the document is in Chinese, the structure and content clearly indicate it is a full annual audited financial report, not just an audit report or a regulatory filing. Therefore, the correct classification is Annual Report (10-K). FY 2018
2019-04-24 Chinese
中信证券股份有限公司关于公司部分募集资金投资项目延期的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the delay in certain investment projects funded by the proceeds from Shenzhen BGI Genomics Co., Ltd.'s initial public offering (IPO). It references regulatory approvals, fundraising amounts, project progress, reasons for delay, and opinions from the board, independent directors, and supervisory board. The document focuses on the status and management of IPO proceeds and project delays, not on financial results or earnings. It is not an annual or interim report, earnings release, or audit report. It is also not a simple announcement or certification but a formal verification opinion related to fundraising project delays. This fits best under Capital/Financing Update (CAP) as it deals with fundraising proceeds and their investment project status and adjustments.
2019-04-24 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.